The United States of America, As Represented by the Secretary, Department of Health and Human Services

Xin-Xing Gu

John B Robbins

Chao-Ming Tsai

David J Lim

The invention relates to intranasal immunization with detoxified lipooligosaccharide from nontypeableor

[object Object]

The present invention relates to peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines.

Peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines

A conjugate vaccine for ( ) comprising isolated lipooligosaccharide from which esterified fatty acids have been removed, to produce a detoxified lipooligosaccharide (dLOS), or from which lipid A has been removed, to produce a detoxified oligosaccharide (OS), which is linked to an immunogenic carrier. The vaccine is useful for preventing otitis media and respiratory infections caused by in mammals, including humans.

Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans

A conjugate vaccine for Nontypeable comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.

Conjugate vaccine for nontypeable Haemophilus influenzae

A conjugate vaccine for comprising lipooligosaccharide which does not contain a lacto-N-tetraose antigen from which at least one primary O-linked fatty acid has been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of meningitis and septic shock in mammals.

Conjugate vaccine for Neisseria meningitidis

A conjugate vaccine for Nontypeable,comprising lipooligosaccharide from which esterified fatty acids have been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of otitis media and respiratory infections in mammals.

Growing community of inventors

Rockville, MD, United States of America

Xin-Xing Gu